سعر امبلانون نكست 68 مجم زرعة 2024

Etonogestrel 68 mg radiopaque subdermal contraceptive implant (1 implant in applicator), Organon, distributed via Multipharma, Egypt.

• Prevention of pregnancy in women of reproductive potentialPopulation: Women of reproductive potentialDailyMed (U.S. National Library of Medicine)

• Most common reason for discontinuation was bleeding irregularities (11.1%); others leading to discontinuation in >=1%: emotional lability (2.3%), weight increase (2.3%), headache (1.6%), acne (1.3%) and depression (1.0%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known or suspected pregnancy; current or past thrombosis or thromboembolic disorders; benign or malignant liver tumours or active liver disease; undiagnosed abnormal uterine bleeding; known, suspected or past breast cancer or other progestin-sensitive cancer; allergic reaction to any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: improper insertion increases the risk of complications (pain, paraesthesia, bleeding, haematoma, scarring, infection, deep insertion, migration including into the pulmonary artery); proper training is required (US: restricted REMS programme).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Expect changes in menstrual bleeding patterns; be alert to ectopic pregnancy; remove if thrombosis occurs; ovarian cysts, liver disease (remove if jaundice), weight gain, elevated blood pressure, gallbladder disease, mild glucose/lipid effects, depressed mood and fluid retention may occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Return to ovulation is rapid: pregnancies occurred as early as 7-14 days after removal, so restart contraception immediately if continued protection is wanted.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4 inducers (e.g. efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, St John's wort)May decrease etonogestrel concentrations and contraceptive effectiveness; use a non-hormonal back-up method during and for 28 days after the inducer.DailyMed (U.S. National Library of Medicine)
• Strong or moderate CYP3A4 inhibitors; HIV protease inhibitors / NNRTIsCYP3A4 inhibitors may increase progestin levels; HIV antiretrovirals may increase or decrease them.DailyMed (U.S. National Library of Medicine)
• Cyclosporine; lamotrigineHormonal contraceptives may increase (e.g. cyclosporine) or decrease (e.g. lamotrigine) plasma concentrations of other drugs.DailyMed (U.S. National Library of Medicine)

• Contraindicated during pregnancy because there is no need for pregnancy prevention in a woman who is already pregnant; remove the implant if pregnancy is maintained. Epidemiologic studies and meta-analyses have not shown an increased risk of birth defects after maternal exposure to low-dose combined hormonal contraceptives before conception or in early pregnancy; no adverse developmental outcomes in rats and rabbits.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Small amounts of etonogestrel pass into human milk without significant adverse effects observed in infants; hormonal contraceptives can reduce milk production.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.